First Patient Dosed in Phase 1 Trial of MM-310 as Treatment for Ovarian, Other Cancers

First Patient Dosed in Phase 1 Trial of MM-310 as Treatment for Ovarian, Other Cancers
The first patient has been dosed in a Phase 1 trial of MM-310 as a treatment for solid tumors, according to its developer, Merrimack Pharmaceuticals. MM-310 is an EphA2 receptor-targeted vesicle -- or fluid-containing sac -- that carries a taxane to tumor cells. A taxane is a therapy that stops cell growth by preventing cells from dividing. Merrimack said MM-310 has fewer side effects than another taxane, Taxotere (doxetacel). The first patient in the MM-310 trial was dosed at Honor Health in Scottsdale, Arizona. Patients at four other U.S. sites are expected to take part in the study.  "The initiation of this study is an important step in evaluating MM-310's safety and preliminary activity in patients diagnosed with solid tumors," Vasileios Askoxylakis, MD, PhD, Merrimack's medical director and MM-310 project leader, said in a press release. "MM-310 was designed to maximize targeted delivery and local activation of a newly engineered and proprietary prodrug of docetaxel, a broadly-used potent chemotherapy that is often associated with significant drug-related toxicities, with a goal of minimizing exposure to healthy tissue," he said. "In several preclinical models, MM-310 not only demonstrated superior antitumor activity when compared to free docetaxel, but also fewer hematologic [blood-related] toxicities. We look forward to continuing MM-310's development via this study." The EphA2 receptor is believed to be expressed at high levels in 50 to 100 percent of major tumor types. They include cancers of the lungs, breast, ovaries, prostate, bladder, panc
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *